Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug257 | Allopurinol Wiki | 1.00 |
| drug3363 | Rifampicin Wiki | 0.41 |
| drug1116 | Cyclosporine Wiki | 0.26 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D051436 | Renal Insufficiency, Chronic NIH | 0.58 |
| D007674 | Kidney Diseases NIH | 0.46 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0012622 | Chronic kidney disease HPO | 0.58 |
| HP:0000077 | Abnormality of the kidney HPO | 0.46 |
Navigate: Correlations HPO
There are 3 clinical trials
This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval
Description: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis
Measure: Maximum observed plasma concentration (Cmax) Time: Visit 2,3,4:- Day 1: Pre-dose, 0.5,1,1.5,2, 3, 4, 5, 6, 7, 8 and 12 hours post-dose; Day 2: 24 and 36 hours post-dose; Day 3: 48 hours post-doseDescription: To assess the effect of a single dose of verinurad given as either a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supra-therapeutic exposure), both in combination with allopurinol 300 mg, on the QTcF interval compared to placebo using a concentration-QTcF interval analysis
Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF) Time: Screening; Visit 2,3,4:- Day -1, 1,2, 3; Follow up visit (7 to 10 days after the last dose)Description: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation(supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected heart rate (ΔHR) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted heart rate (ΔΔHR) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected RR interval (ΔRR interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted RR interval (ΔΔRR interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected PR interval (ΔPR interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted PR interval (ΔΔPR interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔQRS interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted QRS interval (ΔΔQRS interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected QT interval (ΔQT interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted QT interval (ΔΔQT interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected QTcF interval (ΔQTcF interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To investigate the effect of verinurad given either as a 24 mg ER8 formulation (therapeutic exposure) or a 40 mg IR formulation (supratherapeutic exposure), both in combination with allopurinol 300 mg
Measure: Baseline-corrected and placebo-adjusted QTcF interval (ΔΔQTcF interval) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To assess the pharmacokinetics (PK) of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Area under plasma concentration-time curve from zero to infinity (AUC) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects.
Measure: Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUC0-t) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Maximum observed plasma concentration (Cmax) Time: Visit 2,3, and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2,3,4,5,6, 8 and 12 hour (h); Day 2: 24 and 36 h post-dose; Day 3: 48 h post doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Time to reach maximum observed plasma concentration (tmax) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Time delay between drug administration and the first observed concentration in plasma (tlag) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Time of last quantifiable plasma concentration (tlast) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Apparent total body clearance of drug from plasma after extravascular administration (parent drug only) [CL/F] Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Apparent volume of distribution during the terminal phase after extravascular administration (parent drug only) [Vz/F] Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Apparent volume of distribution at steady state (Vss/F) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess the PK of verinurad and its metabolites (M1 and M8) and allopurinol and its metabolite (oxypurinol) in healthy subjects
Measure: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRT) Time: Visit 2, 3 and 4:- Day 1: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose; Day 2: 24 and 36 h post-dose; Day 3: 48 h post-doseDescription: To assess clinical chemistry/hematology/urinalysis as a variable of safety and tolerability of verinurad and allopurinol
Measure: Number of subjects with abnormal haematology, clinical chemistry and urinalysis Time: Screening; Visit 2,3 and 4:- Day -1, Day 3: 48 h post-dose, Follow up periodDescription: To assess vital signs as a variable of safety and tolerability of verinurad and allopurinol
Measure: Number of subjects with abnormal blood pressure and pulse rate Time: Screening; Visit 2,3 and 4:- Day -1, Day 1: pre-dose, 1 and 6 h post-dose; Day 2: 24 h post-dose; Day 3: 48 h post-dose, Follow up visitThis Phase 1 study aims to quantify the effects of cyclosporine, a broad transporter inhibitor, and rifampicin, an OATP1B1/3 inhibitor, on verinurad pharmacokinetics (PK). The study is conducted in accordance with Food and Drug Administration guidance on Clinical Drug Interaction Studies, 2020. Verinurad will be developed as a fixed combination since it will always be administered together with allopurinol.
Description: Verinurad Cmax ratio of geometric mean of test treatment (verinurad+allopurinol with (cyclosporine or rifampicin), relative to reference treatment (verinurad+allopurinol alone) in each treatment period
Measure: Geometric mean ratio of maximum observed plasma peak concentration (Cmax) for verinurad Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Verinurad AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of area under plasma concentration-time curve from time zero to infinity (AUCinf) for verinurad Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Verinurad AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of area under the plasma concentration-time curve from zero to time of last quantifiable concentration (AUClast) for verinurad Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of Cmax for verinurad metabolite: M1 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of Cmax for verinurad metabolite: M8 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUCinf for verinurad metabolite: M1 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUCinf for verinurad metabolite: M8 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUClast for verinurad metabolite: M1 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUClast for verinurad metabolite: M8 Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Allopurinol Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of Cmax for allopurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Allopurinol AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUCinf for allopurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Allopurinol AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUClast for allopurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Oxypurinol Cmax ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of Cmax for oxypurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Oxypurinol AUCinf ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUCinf for oxypurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Oxypurinol AUClast ratio of geometric means of test treatment, relative to reference treatment in each treatment period
Measure: Geometric mean ratio of AUClast for oxypurinol Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Cmax of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Cmax Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUCinf of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: AUCinf Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUClast of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: AUClast Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: AUC(0-24) of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Area under the concentration-time curve from time zero to 24 hours post-dose [AUC(0-24)] Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: tmax of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Time to reach peak or maximum observed concentration following drug (tmax) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: t½λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: λz of verinurad, M1, M8, allopurinol and oxypurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Terminal elimination rate constant (λz) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: CL/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Apparent total body clearance of drug from plasma after extravascular administration (CL/F) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: MRTinf of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Mean Residence Time of the unchanged drug in the systemic circulation (MRTinf) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Vss/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Volume of distribution (apparent) at steady state following extravascular administration (Vss/F) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Vz/F of verinurad and allopurinol when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: MP ratio of Cmax for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: Metabolite:Parent (MP) ratio of Cmax Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: MP ratio of AUCinf for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: MP ratio of AUCinf Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: MP ratio of AUClast for verinurad when verinurad+allopurinol administered alone or in combination with cyclosporine or rifampicin in each treatment period
Measure: MP ratio of AUClast Time: Days 1 to 5: 30 minutes pre-dose and up to 96 hours post-doseDescription: Observed values and change from baseline value in systolic and diastolic BP for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal blood pressure (BP) Time: For approximately 9 weeks (from screening to follow-up)Description: Observed values and change from baseline value in pulse rate for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal pulse rate Time: For approximately 9 weeks (from screening to follow-up)Description: Observed values and change from baseline value in temperature for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal temperature Time: For approximately 9 weeks (from screening to follow-up)Description: 12-lead resting ECG safety assessments if there are any abnormal findings for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal 12-lead electrocardiogram (ECG) Time: At screening and post-treatment follow-up visit (7-14 day after last dose of verinurad)Description: Any new or aggravated clinically relevant abnormal medical physical examination finding compared to the baseline assessment for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal physical examination Time: For approximately 9 weeks (from screening to follow-up)Description: Observed values and change from baseline value in hematology parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal hematology parameters Time: At screening, Day -1, Day 3 (Treatment Periods 1, 2 and 3) and post-treatment follow-up (7-14 days after last dose of verinurad)Description: Observed values and change from baseline value in clinical chemistry parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal clinical chemistry parameters Time: At screening, Day -1 (Treatment Periods 1 and 3), Day 1, Day 2 and Day 3 (Treament Period 1), and post-treatment follow-up (7-14 days after last dose of verinurad)Description: Observed values and change from baseline value in urinalysis parameters for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with abnormal urinalysis parameters Time: At screening, Day -1 (Treatment Periods 1 and 3), Day 1, Day 2 and Day 3 (Treament Period 1), and post-treatment follow-up (7-14 days after last dose of verinurad)Description: The number and percentage of subjects with AEs and the number of events for subjects administered with verinurad and allopurinol in combination with cyclosporine or rifampicin
Measure: Number of subjects with adverse events (AEs) and serious AEs Time: For approximately 9 weeks (from screening to follow-up)This study is a single centre, randomised, open-label, single-dose, 3-period, 3-treatment, crossover study in healthy male and female subjects. This study is intended to assess the relative bioavailability between the ph3 (fixed dose combination) and ph2b (free combination) formulations of verinurad and allopurinol. For verinurad, both formulations have an extended release profile. For allopurinol, both formulations have an immediate release profile.
Description: Area under plasma concentration time curve from time zero to infinity (AUCinf) of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by AUCinf Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUClast) of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by AUClast Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Maximum observed plasma (peak) drug concentration (Cmax) of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 and ph2b formulations under fasted conditions by Cmax Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by AUCinf Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by AUClast Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.
Measure: Evaluation of the relative bioavailability of verinurad, allopurinol and oxypurinol after dosing with the ph3 formulation under fed and fasted conditions by Cmax Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Area under plasma concentration time curve from time zero to infinity of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by AUCinf Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by AUClast Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Maximum observed plasma (peak) drug concentration of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Cmax Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Time to reach maximum observed plasma concentration following drug administration (tmax) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by tmax Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Time delay between drug administration and the first observed concentration in plasma (tlag) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by tlag Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Terminal elimination rate constant (λz) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by λz Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Half life associated with terminal slope (λz) of a semi logarithmic concentration time curve (t½λz) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by t½λz Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Apparent total body clearance of drug from plasms after extravascular administration (parent drug only) (CL/F) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by CL/F Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Mean residence time of the unchanged drug in the systemic circulation from zero to infinity (MRTinf) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by MRTinf Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Volume of distribution (apparent) at steady state following extravascular administration (Vss/F) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Vss/F Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F) of verinurad, allopurinol and oxypurinol.
Measure: Assessment of the pharmacokinetic profiles of verinurad, allopurinol and oxypurinol when administered as the ph3 formulation under fed and fasted conditions and the ph2b formulation in the fasted state by Vz/F Time: Days 1 to 4: pre-dose and upto 72 hours post-doseDescription: Assessment of the safety of single doses of verinurad and allopurinol.
Measure: Number of subjects with serious and non-serious adverse events Time: From Screening (Days -28 to -2) to follow-up visit (7 to 14 days post final dose)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports